Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Monteiro, Cátia ^a,b   Sousa, Marta Velho ^a   Ribeiro, Ricardo ^a,b,c   Maurício, Joaquina ^a   Fraga, Avelino ^a,d   Medeiros, Rui ^a,b,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b LPCC   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d Centro Hospitalar e Universitário do Porto   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Androgen receptor; Androgens; Castration resistant prostate cancer; Genetic polymorphism; Pharmacogenetic

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN;

ADOLESCENT; ADVANCED CANCER; ARTICLE; CANCER RISK; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; EXON; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; AGED; DRUG RESISTANCE; GENETICS; MIDDLE AGED; NEOPLASM; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEX HORMONE-BINDING GLOBULIN;

EID: 84873349067     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0490-2     Document Type: Article

References (35)

1. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371(9625):1710-21. doi: 10.1016/S0140-6736(08)60729-1.
2. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025.
3. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010;17(4):R305-15. doi: 10.1677/ERC-10-0187.
4. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26(2):162-73.
5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506-13.
6. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025-33. doi: 10.1200/JCO.2004.06.037.
7. Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, et al. Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet. 2003;141(2):91-6.
8. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008;26(6):842-7. doi: 10.1200/JCO.2007.13.6804.
9. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res. 2008;14(11):3367-71. doi: 10.1158/1078-0432.CCR-07-5119.
10. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther. 2005;4(11):1222-5.
11. Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9(5):341-6. doi: 10.1038/tpj.2009.20.
12. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29(18):2565-73. doi: 10.1200/JCO.2010.31.2405.
13. Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E. Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005;15(5):339-40.
14. Bocchinfuso WP, Ma KL, Lee WM, Warmels-Rodenhiser S, Hammond GL. Selective removal of glycosylation sites from sex hormone-binding globulin by site-directed mutagenesis. Endocrinology. 1992;131(5):2331-6.
15. Cousin P, Dechaud H, Grenot C, Lejeune H, Pugeat M. Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. J Clin Endocrinol Metab. 1998;83(1):235-40.
16. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039.
17. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.
18. Cabrespine A, Guy L, Chollet P, Debiton E, Bay JO. Molecular mechanisms involved in hormone resistance of prostate cancer. Bull Cancer. 2004;91(10):747-57.
19. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927-41. doi: 10.1200/JCO.2004.04. 579.
20. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34-45. doi: 10.1038/35094009.
21. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112(6):1247-53. doi: 10.1002/cncr.23304.
22. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118-26.
23. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108(3):418-24. doi: 10.1002/ijc.11572.
24. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(1):165-8. doi: 10.1158/1055-9965.EPI-06-0689.
25. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S, et al. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer. 2006;56(1):31-9. doi: 10.1207/s15327914nc5601-5.
26. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(5):969-78. doi: 10.1158/1055-9965.EPI- 06-0767.
27. Haiman CA, Riley SE, Freedman ML, Setiawan VW, Conti DV, Le Marchand L. Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab. 2005;90(4):2198-204. doi: 10.1210/jc.2004-1417.
28. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011;57(10):1366-75. doi: 10.1373/clinchem.2011.165977.
29. Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol. 2010;2(2):107-23. doi: 10.1177/1758834009356433.
30. Ribeiro ML, Santos A, Carvalho-Salles AB, Hackel C. Allelic frequencies of six polymorphic markers for risk of prostate cancer. Braz J Med Biol Res. 2002;35(2):205-13.
31. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55(9):1937-40.
32. Zhuo FL, Xu W, Wang L, Wu Y, Xu ZL, Zhao JY. Androgen receptor gene polymorphisms and risk for androgenetic alopecia: a meta-analysis. Clin Exp Dermatol. 2012;37(2):104-11. doi: 10.1111/j.1365-2230.2011.04186.x.
33. Lindstrom S, Adami HO, Balter KA, Xu J, Zheng SL, Stattin P, et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res. 2007;13(17):5156-61. doi: 10.1158/1078-0432.CCR-07-0669.
34. Lindstrom S, Ma J, Altshuler D, Giovannucci E, Riboli E, Albanes D, et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010;95(9):E121-7. doi: 10.1210/jc.2009-1911.
35. Mononen N, Seppala EH, Duggal P, Autio V, Ikonen T, Ellonen P, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 2006;66(2):743-7. doi: 10.1158/0008-5472.CAN-05-1723.